Product Candidates

For the treatment of chronic hepatitis C, we are developing ANA598, a non-nucleoside polymerase inhibitor, and ANA773, an oral TLR7 agonist prodrug. We are also developing ANA773 for the treatment of cancer. Both ANA598 and ANA773 are wholly owned by Anadys.